Publication:
Predictors of long-term disability accrual in relapse-onset multiple sclerosis.

No Thumbnail Available

Date

2016-06-01

Authors

Jokubaitis, Vilija G
Spelman, Tim
Kalincik, Tomas
Lorscheider, Johannes
Havrdova, Eva
Horakova, Dana
Duquette, Pierre
Girard, Marc
Prat, Alexandre
Izquierdo, Guillermo

Advisors

Journal Title

Journal ISSN

Volume Title

Publisher

Metrics
Google Scholar
Export

Research Projects

Organizational Units

Journal Issue

Abstract

To identify predictors of 10-year Expanded Disability Status Scale (EDSS) change after treatment initiation in patients with relapse-onset multiple sclerosis. Using data obtained from MSBase, we defined baseline as the date of first injectable therapy initiation. Patients need only have remained on injectable therapy for 1 day and were monitored on any approved disease-modifying therapy, or no therapy thereafter. Median EDSS score changes over a 10-year period were determined. Predictors of EDSS change were then assessed using median quantile regression analysis. Sensitivity analyses were further performed. We identified 2,466 patients followed up for at least 10 years reporting post-baseline disability scores. Patients were treated an average 83% of their follow-up time. EDSS scores increased by a median 1 point (interquartile range = 0-2) at 10 years post-baseline. Annualized relapse rate was highly predictive of increases in median EDSS over 10 years (coeff = 1.14, p = 1.9 × 10(-22) ). On-therapy relapses carried greater burden than off-therapy relapses. Cumulative treatment exposure was independently associated with lower EDSS at 10 years (coeff = -0.86, p = 1.3 × 10(-9) ). Furthermore, pregnancies were also independently associated with lower EDSS scores over the 10-year observation period (coeff = -0.36, p = 0.009). We provide evidence of long-term treatment benefit in a large registry cohort, and provide evidence of long-term protective effects of pregnancy against disability accrual. We demonstrate that high annualized relapse rate, particularly on-treatment relapse, is an indicator of poor prognosis. Ann Neurol 2016;80:89-100.

Description

MeSH Terms

Adult
Disability Evaluation
Female
Follow-Up Studies
Glatiramer Acetate
Humans
Interferon-beta
Male
Multiple Sclerosis
Pregnancy
Prognosis
Protective Factors
Recurrence
Registries
Risk Factors
Young Adult

DeCS Terms

CIE Terms

Keywords

Citation